Friday 22 November 2024

The Pharma Letter Podcast — Episode 24 — Lilly looks to lead in Alzheimer's

Biotechnology
Simon Wentworth
17 July 2023
pharma_letter_podcast_24

More on this story...

Biotechnology
BRIEF—AAIC 2023: Prothena offers data on BMS-partnered antibody
12 July 2023
Biotechnology
Lilly breakthrough offers real hope for people with early Alzheimer's
17 July 2023
Pharmaceutical
Lotus to market Corium's Alzheimer's patch in Southeast Asia
11 August 2023
Biotechnology
Coya Therapeutics expands COYA 302 into Alzheimer’s disease
21 February 2024


Companies featured in this story

More ones to watch >


Today's issue

Amid RFK Jr vaccine worries, FDA’s Peter Marks remains calm
Pharmaceutical
Amid RFK Jr vaccine worries, FDA’s Peter Marks remains calm
22 November 2024
Biotechnology
Versant Ventures unveils obesity focused Pep2Tango Therapeutics
22 November 2024
Biotechnology
Sino Biopharm to work with LaNova on LM-108
22 November 2024
Biotechnology
FDA panel flags risks as AstraZeneca seeks full Andexxa approval
22 November 2024
Biotechnology
Enveda closes $130 million Series C funding
22 November 2024
Biotechnology
Alloy and Takeda team up on CAR-T cell platform
21 November 2024
Pharmaceutical
Eisai announces launch of Rozebalamin and Tasfygo
21 November 2024

Company Spotlight

A Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.




More Features in Biotechnology

Versant Ventures unveils obesity focused Pep2Tango Therapeutics
22 November 2024
Sino Biopharm to work with LaNova on LM-108
22 November 2024
FDA panel flags risks as AstraZeneca seeks full Andexxa approval
22 November 2024
Enveda closes $130 million Series C funding
22 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze